Anemia Management News

Otsuka Pharmaceutical Co. Ltd. recently announced it is terminating agreements with Akebia Therapeutics for development of vadadustat in the U.S. market.

The decision by the FDA not to approve vadadustat for patients on dialysis was surprising and disappointing to nephrologists hoping for a safe and effective oral alternative to erythropoiesis-stimulating agents for treatment of anemia.

Patients with chronic kidney disease and their care partners report a considerable burden, especially when the patients also have anemia, according to data published in Kidney Medicine.

The FDA has accepted a new drug application for daprodustat, which was filed by GlaxoSmithKline plc, according to a press release.

BOSTON — New research presented during the late-breaking trials program at the National Kidney Foundation Spring Clinical Meetings showed the anemia drug daprodustat has cardiovascular benefits comparable to erythropoiesis-stimulating agents.

The FDA rejected Akebia Therapeutics’ anemia drug vadadustat for use in patients with chronic kidney disease, citing concerns about vascular access complications and liver toxicity.

According to published results, preoperative anemia was associated with an increased risk for complications, non-home discharge and unplanned readmission in patients who underwent total knee arthroplasty.

Patients with chronic kidney disease and heart failure who took the sodium glucose co-transporter 2 inhibitor empagliflozin saw a stabilization of ejection fraction and a slowing in eGFR decline, according to trial results presented here.

The oral anemia drug daprodustat showed noninferiority to erythropoiesis-stimulating agents for achieving targeted hemoglobin levels and cardiovascular risk in patients with kidney disease on dialysis and not on dialysis, according to phase 3 data presented at ASN Kidney Week.

Less frequent, higher doses of iron supplementation for patients on hemodialysis did not meet noninferiority standards for maintaining hemoglobin levels compared with the traditional treatment of more frequent doses, according to a study.